日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma

一项针对晚期肉瘤患者的 I 期研究,评估 CSF1R 抑制剂 vimseltinib 与 PD-L1 抑制剂 avelumab 联合用药的疗效。

E Rosenbaum ,K Seier ,M Bradic ,S Movva ,C M Kelly ,M A Dickson ,M L Keohan ,M M Gounder ,P Chi ,B A Nacev ,J E Chan ,V Avutu ,M Biniakewitz ,S Jasnani ,M Duchemin ,R Desir ,P Wong ,J Erinjeri ,S Hwang ,C R Antonescu ,L-X Qin ,W D Tap ,S P D'Angelo

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results

CHK1/2激酶抑制剂ACR-368治疗复发或难治性促纤维增生性小圆细胞肿瘤患者的I/II期临床试验结果

Slotkin, Emily K; Mauguen, Audrey; Dela Cruz, Filemon S; Ortiz, Michael V; Avutu, Viswatej; Meyers, Paul A; Wexler, Leonard H; O'Donohue, Tara J; Kinnaman, Michael D; Kelly, Ciara M; D'Angelo, Sandra P; Keohan, Mary Lou; Gounder, Mrinal M; Thornton, Katherine; Nacev, Benjamin A; Chi, Ping; Rosenbaum, Evan; Dickson, Mark; Pachhal, Sagarika; Somwar, Romel; Ladanyi, Marc; Robb, Caroline; Pandit-Taskar, Neeta; Hwang, Sinchun; Price, Anita; Behr, Gerald; Reed, Damon R; Kentsis, Alex; Kung, Andrew L; Bender, Julia Glade; Tap, William D